Key result
Higher plasma MCP-1 shows no independent link to prevalent CAC after age adjustment.
Why the study?
Plasma levels of MCP-1 are independently associated with prognosis in acute coronary syndromes, but few population-based data exist in earlier atherosclerosis stages.
Cross-Sectional (n=3,499)
No
Answers are grounded in this paper and cite their sources.
Observational study reveals circulating monocyte chemoattractant protein-1 associates with early cardiovascular risk factors and subclinical atherosclerosis, highlighting its role in vascular disease.
OBJECTIVES: We sought to evaluate the association between plasma levels of monocyte chemoattractant protein (MCP)-1 and the risk for subclinical atherosclerosis. BACKGROUND: Monocyte chemoattractant protein is a chemokine that recruits monocytes into the developing atheroma and may contribute to atherosclerotic disease development and progression. Plasma levels of MCP-1 are independently associated with prognosis in patients with acute coronary syndromes, but few population-based data are available from subjects in earlier stages of atherosclerosis. METHODS: In the Dallas Heart Study, a population-based probability sample of adults in Dallas County </=65 years old, plasma levels of MCP-1 were measured in 3,499 subjects and correlated with traditional cardiovascular risk factors, high-sensitivity C-reactive protein (hs-CRP), and coronary artery calcium (CAC) measured by electron beam computed tomography. RESULTS: Higher MCP-1 levels were associated with older age, white race, family history of premature coronary disease, smoking, hypertension, diabetes, hypercholesterolemia, and higher levels of hs-CRP (p < 0.01 for each). Similar associations were observed between MCP-1 and risk factors in the subgroup of participants without detectable CAC. Compared with the subjects in the lowest quartile of MCP-1, the odds of prevalent CAC (CAC score >/=10) for subjects in the second, third, and fourth quartiles were 1.30 (95% confidence interval [CI] 0.99 to 1.73), 1.60 (95% CI 1.22 to 2.11), and 2.02 (95% CI 1.54 to 2.63), respectively. The association between MCP-1 and CAC remained significant when adjusted for traditional cardiovascular risk factors, but not when further adjusted for age. CONCLUSIONS: In a large population-based sample, plasma levels of MCP-1 were associated with traditional risk factors for atherosclerosis, supporting the hypothesis that MCP-1 may mediate some of the atherogenic effects of these risk factors. These findings support the potential role of MCP-1 as a biomarker target for drug development.
No takes yet. Share an insight, caveat, or question.
Deo et al. (2004) conducted a cross-sectional in Subclinical atherosclerosis (n=3,499). Plasma levels of monocyte chemoattractant protein-1 (MCP-1) vs. Lowest quartile of MCP-1 was evaluated on Prevalent coronary artery calcium (CAC score ≥10) (OR 2.02, 95% CI 1.54-2.63). Higher plasma MCP-1 levels were associated with increased odds of prevalent coronary artery calcium, but not after adjusting for age.
Synapse has enriched 10 related papers. Consider them for comparative context: